朱成義,伊瓊,馬金力,韋企平

活血通絡(luò)顆粒對缺血性視神經(jīng)病變的臨床研究

朱成義1,伊瓊1,馬金力1,韋企平2

作者單位:1(100013)中國北京市和平里醫(yī)院眼科;2(100078)中國北京市,北京中醫(yī)藥大學(xué)東方醫(yī)院眼科

目的:探討活血通絡(luò)顆粒對氣虛血瘀型非動脈炎性前部缺血性視神經(jīng)病變的臨床療效。

視神經(jīng)病變;血流變學(xué);活血通絡(luò)顆粒

引用:朱成義,伊瓊,馬金力,等.活血通絡(luò)顆粒對缺血性視神經(jīng)病變的臨床研究.國際眼科雜志2015;15(11):1945-1948

0 引言

非動脈炎性前部缺血性視神經(jīng)病變(non arteritic anterior ischemic opticneuropathy,NAION)是一種50歲以上人群中最常見的急性視神經(jīng)病變,臨床上以無痛性突發(fā)視力障礙、視野缺損、視盤水腫或周圍神經(jīng)纖維層出血為主要表現(xiàn)[1-2]。該病發(fā)病急、短期內(nèi)視力急劇下降,嚴重者甚至失明[3]。目前,國內(nèi)在控制原發(fā)病的基礎(chǔ)上,對NAION治療多采用復(fù)方樟柳堿顳淺動脈旁皮下注射,但療效尚不盡滿意。本研究結(jié)合中醫(yī)辯證思維,旨在探討復(fù)方樟柳堿治療的基礎(chǔ)上應(yīng)用活血通絡(luò)顆粒對氣虛血瘀型NAION的臨床療效。

1 對象和方法

1.1 對象選取2014-02/10在我院眼科門診及住院的患者100例,其中雙眼發(fā)病42例,單眼發(fā)病58例,共計142眼;男性患者51例,女性患者49例。伴隨的全身疾病包括高血壓31例44眼,糖尿病27例38眼,冠狀動脈硬化29例42眼,無明顯誘因13例18眼。納入標準:符合以下診斷標準,同時自愿配合該項目治療的患者被納入為研究對象。參照Hayreh等[4]制定的NAION診斷標準:(1)突發(fā)視力下降,多在晨起時發(fā)生;(2)病史中急性期存在視盤水腫或相關(guān)的記錄;(3)存在與視盤病變相關(guān)的視野缺損;(4)排除其他可以導(dǎo)致視盤水腫和視力下降的神經(jīng)、系統(tǒng)或眼部疾病。氣虛血瘀證型診斷標準[5]:視力驟降,心煩郁悶,頭目隱痛,胸脅脹滿;舌質(zhì)紫暗或有瘀斑,脈弦數(shù)。采用隨機對照試驗,將100例隨機分為治療組和對照組,其中治療組51例72眼,對照組49例70眼。兩組患者的性別、年齡、病程的差異均無統(tǒng)計學(xué)意義(P＞0.05),見表1。

1.2 方法對照組采用復(fù)方樟柳堿注射液2mL顳淺動脈旁注射,1次/d。在上述治療的基礎(chǔ)上,治療組根據(jù)韋企平[5]主編的《視神經(jīng)疾病中西醫(yī)結(jié)合診治》氣虛血瘀型方選活血通絡(luò)方,方藥組成:熟地15g、當歸、芍藥、川芎、雞血藤、絲瓜絡(luò)、路路通、女貞子各10g、太子參15g、紅花、炒枳殼各6g。上方由北京中醫(yī)藥大學(xué)東方醫(yī)院制劑室制成配方顆粒,每次10g,每天2次早晚飯后服用。兩組療程均為3mo。釆用國際標準對數(shù)視力表對患者的視力進行檢查;采用靜態(tài)自動電腦Octpus101型視野計檢查患者60°范圍的視野;眼底熒光血管造影(Fundus fluoresecine angiography,FFA)觀察眼底血管情況;采用血液流變儀檢測血液流變學(xué)指標;采用生化分析儀檢測血脂、血糖、肝腎功能等指標。記錄兩組患者用藥前后上述指標的變化,并對結(jié)果進行比較分析。

療效標準[6]:以視力、視野的改善程度為標準,將療效分為以下4類:(1)臨床治愈:視力≥1.0或增加4行,從光感提高至0.1,從眼前指數(shù)提高至0.2,從0.02提高至0.3,或從0.05提高至0.4,視野缺損面積減少40%以上,或平均視野閾值增加30%以上;(2)顯效:視力增加3行,從光感提高至0.05,從眼前指數(shù)提高至0.1,從0.01提高至0.2,從0.05提高至0.3,視野缺損面積減少15%～40%或平均視野閾值增加10%～30%;(3)有效:視力增加2行或1行,從光感提高至0.02,從眼前指數(shù)提高至0.02～0.05,從0.02提高至0.05～0.1,從0.05提高至0.12～0.2,視野缺損面積減少15%以下,或平均視野閾值增加10%以下;(4)無效:視力無變化或下降,視野缺損面積不變或增大,或平均視野閾值不變或下降。

表1 患者的一般情況比較

表2 治療組和對照組總體治療效果的比較例(眼)

表3 治療組和對照組視力和視野平均敏感度的比較±s

表3 治療組和對照組視力和視野平均敏感度的比較±s

aP＜0.05 vs對照組治療后;cP＜0.05 vs對照組治療前;eP＜0.05 vs治療組治療前。

組別例數(shù)時間視力視野平均敏感度對照組49治療前0.29±0.09 16.81±3.15治療后0.35±0.06c21.89±3.36c治療組51治療前0.28±0.08 16.24±2.84治療后0.43±0.09a,e24.24±2.22a,e

統(tǒng)計學(xué)分析:采用SPSS 18.0軟件進行統(tǒng)計學(xué)分析,活血通絡(luò)顆粒對氣虛血瘀型NAION的臨床總體療效采用Wilcoxon秩和檢驗;兩組的視力、視野、血脂和血液流變學(xué)指標的治療前后比較分別采用配對t檢驗,兩組之間治療前后比較分別采用獨立樣本t檢驗,以±s表示, P＜0.05有統(tǒng)計學(xué)意義。

2 結(jié)果

2.1 總體療效的分析治療后,治療組患者臨床治愈12例15眼(23.5%),顯效15例21眼(29.4%),有效18例25眼(35.3%),無效6例11眼(11.8%),有效率為88.2%;對照組患者臨床治愈5例7眼(10.2%),顯效8例11眼(16.3%),有效22例29眼(44.9%),無效14例23眼(28.6%),有效率為71.4%。兩組臨床總體療效比較用Wilcoxon秩和檢驗差異有統(tǒng)計學(xué)意義(Z=2.890,P= 0.004,表2)。

2.2 視力和視野的改善情況治療后,和對照組比較,治療組患者的視力顯著提高,差異均有統(tǒng)計學(xué)意義(t=-4.65, P＜0.01);治療組患者的視野平均敏感度顯著提高,差異均有統(tǒng)計學(xué)意義(t=-3.69,P=0.0004)。治療后和治療前比較,兩組患者的視力均提高,差異有統(tǒng)計學(xué)意義(t= -3.86,P=0.0002;t=-7.68,P＜0.01);兩組患者的視野平均敏感度均提高,差異有統(tǒng)計學(xué)意義(t=-6.98,P＜0.01;t=-14.03,P＜0.0001),見表3。

2.3 血脂的分析治療前,治療組與對照組患者的血清總膽固醇(TC)、甘油三脂(TG)、高密度脂蛋白膽固醇(HDL-C)、低密度脂蛋白膽固醇(LDL-C)水平進行比較,均無顯著性差異(P＞0.05)。治療后,和對照組比較,治療組患者的TC、TG、LDL-C水平較治療前均下降,HDL-C水平較治療前升高,差異均有統(tǒng)計學(xué)意義(t=6.25,P＜0.01;t=4.14,P＜0.01;t=4.48,P＜0.01;t=3.76,P= 0.0003;t=-4.31,P＜0.01)。治療后,和治療前自身比較,治療組患者的TC、TG、LDL-C水平較治療前均下降,HDL-C水平較治療前升高,差異有統(tǒng)計學(xué)意義(t=9.83,P＜0.01; t=4.78,P＜0.01;t=4.58,P＜0.01;t=7.22,P＜0.01);對照組患者的上述指標比較,無顯著性差異(t=1.77,P= 0.0807;t=1.25,P=0.2153;t=1.04,P=0.3038;t=-1.89,P= 0.0629),表4。

表4 治療組與對照組血脂水平的比較(±s,mmol/L)

表4 治療組與對照組血脂水平的比較(±s,mmol/L)

aP＜0.05 vs對照組治療后;cP＜0.05 vs治療組治療前。

組別例數(shù)時間TC TG HDL-C LDL-C對照組49治療前8.07±1.07 2.43±0.82 1.44±0.30 4.48±1.19治療后7.59±1.32 2.25±0.48 1.59±0.35 4.25±0.75治療組51治療前8.18±0.93 2.48±0.78 1.40±0.30 4.57±1.08治療后5.84±1.18a,c1.79±0.46a,c1.89±0.30a,c3.50±1.01a,c

表5 治療組與對照組血流變學(xué)指標的比較±s

表5 治療組與對照組血流變學(xué)指標的比較±s

aP＜0.05 vs對照組治療后;cP＜0.05 vs治療組治療前。

組別例數(shù)時間血漿黏度(mP/s)全血低切黏度(mP/s)全血高切黏(mP/s)紅細胞壓積(%)血漿纖維蛋白(mg/dL)對照組49治療前1.67±0.29 12.52±1.97 5.66±1.25 47.17±3.30 3.87±0.89治療后1.55±0.27 11.76±2.84 5.62±1.29 46.12±3.32 3.67±0.90治療組51治療前1.73±0.25 12.43±1.90 5.68±1.25 47.22±3.18 3.92±0.81治療后1.39±0.15a,c8.81±1.57a,c4.77±0.74a,c41.19±4.63a,c3.10±0.71a,c

2.4 血流變學(xué)的分析治療前,治療組與對照組患者的血漿黏度、全血高切黏度、低切黏度、紅細胞壓積指數(shù)及血漿纖維蛋白原水平進行比較,均無顯著性差異(P＞0.05)。治療后,和對照組比較,治療組患者的血漿黏度、全血高切黏度、低切黏度、紅細胞壓積指數(shù)及血漿纖維蛋白原水平均下降,差異有統(tǒng)計學(xué)意義(t=3.40,P=0.0011;t=5.75, P＜0.01;t=3.61,P=0.0005;t=6.78,P＜0.01;t=3.13,P= 0.0025)。治療后,和治療前進行自身比較,治療組患者的上述指標較治療前均下降,差異有統(tǒng)計學(xué)意義(t= 7.51,P＜0.01;t=9.30,P＜0.01;t=3.98,P=0.0002;t= 6.78,P＜0.01;t=4.79,P＜0.01);對照組患者的上述指標進行比較,無顯著性差異(t=1.90,P=0.0606;t=1.40,P= 0.1660;t=0.16,P=0.8744;t=1.42,P=0.1602;t=1.02, P=0.3120),見表5。

3 討論

NAION是50歲以上人群中最常見的急性視神經(jīng)病變,血流動力學(xué)異常、血液黏稠度改變、眼灌注壓較低為其病理生理學(xué)基礎(chǔ)[7-8]。活血通絡(luò)顆粒由熟地、當歸、芍藥、川芎、雞血藤、絲瓜絡(luò)、路路通、女貞子、太子參、紅花、炒枳殼組成,具有益氣活血、通絡(luò)明目的功效。該配方符合氣虛血瘀型NAION患者的恢復(fù)期的證候特點,具有多向調(diào)節(jié)功能。

本研究結(jié)果顯示:治療組患者的視力、視野改善情況總有效率(88.2%)高于對照組患者(71.4%)。該結(jié)果和常永業(yè)等[9]的研究結(jié)果基本一致。另外,治療組患者視力和視野平均敏感度均較對照組顯著性提高。上述結(jié)果提示:在采用復(fù)方樟柳堿注射液治療的基礎(chǔ)上,聯(lián)合應(yīng)用活血通絡(luò)顆粒,在一定程度上可以改善NAION患者的視力、視野。該治療效果與活血通絡(luò)顆粒的成分密切相關(guān)。活血通絡(luò)顆粒中的多種成分:地黃[10-11]、川芎[12-13]、芍藥[14]、雞血藤[15]和枳殼[16]中有效成分可以調(diào)節(jié)多種血管活性物質(zhì)的釋放,對抗交感神經(jīng)的縮血管作用,有擴張微血管、改善視網(wǎng)膜缺血后再灌注產(chǎn)生的損傷。川芎中川芎嗪[17-18]、地黃中梓醇和毛蕊花糖苷[19-21]、紅花中紅花黃色素[22-24]和羥基紅花黃色素A[25-26]、芍藥中芍藥苷[27-30]、太子參中皂苷[31]以及枳殼中柚皮素[32]和橙皮苷[33-34]均對神經(jīng)均有一定的保護作用。

本研究結(jié)果顯示:治療組患者的血清總膽固醇、甘油三脂、低密度脂蛋白膽固醇水平較對照組均下降,高密度脂蛋白膽固醇水平較對照組升高,差異有顯著性意義。該結(jié)果可能與活血通絡(luò)顆粒組方中地黃[35]、紅花[36]、女貞子[37]、太子參[38]、和絲瓜絡(luò)[39]中多種有效成分均可以降低血清膽固醇、甘油三脂、低密度脂蛋白的水平和升高密度脂蛋白的水平。

另外,本研究結(jié)果顯示:治療組患者的血漿黏度、全血高切黏度、低切黏度和血漿纖維蛋白原水平較對照組均顯著下降。該結(jié)果可能因為活血通絡(luò)顆粒配方中地黃的有效成分5-羥甲基糠醛[40-41]、川芎和赤芍中有效成分[42]、枳殼中柚皮素[16]、雞血藤和紅花中有效成分[43]均具有抑制血小板及紅細胞凝聚,降低血液黏滯度,促進纖溶活性,抑制血管內(nèi)凝血,擴張血管,改善微循環(huán)和細胞代謝,增加動脈血流量,降低外周血管阻力的作用。

結(jié)合中醫(yī)辯證論治,活血通絡(luò)顆粒中熟地、當歸、太子參養(yǎng)血活血,補氣生津,使脈充血行,共為主藥;赤芍活血化瘀,白芍柔肝益陰,川芎為血中氣藥,可行氣走竄通絡(luò),其辛香善行之力可直達頭目巔頂,雞血藤養(yǎng)血活血,紅花活血化瘀,通絡(luò)開閉,四藥同為輔藥;佐以枳殼調(diào)理氣機,疏解氣滯,絲瓜絡(luò)味甘、辛平,路路通味苦、辛平,二藥合并可增強其通經(jīng)活絡(luò)功效,性味平緩,毒性小,可持久應(yīng)用;女貞子性味平和,可“強陰,健腰膝,變白發(fā),明目”,加入本方有滋陰增液,生津潤絡(luò)之效,為使藥。全方以活為要,以補助通,藥性和緩,可長服久用。以上諸藥具有益氣養(yǎng)陰、活血化瘀通絡(luò)的作用。

活血通絡(luò)顆粒以中醫(yī)辨證論治和整體觀念為指導(dǎo),對NAION患者視功能的保護作用可能是通過中藥內(nèi)多成分、多重途徑、多個靶點共同實現(xiàn)的?？傊?本研究采用復(fù)方樟柳堿注射液治療的基礎(chǔ)上,聯(lián)合應(yīng)用活血通絡(luò)顆粒,進一步改善了NAION患者的視力、視野、血脂水平及血液流變學(xué)指標,在用藥過程中無明顯不良反應(yīng),具有一定的臨床借鑒意義。

1 Verma R,Gupta M,Chaudhari TS.Neurogenic vision loss:Causes and outcome.An experience from a tertiary center in Northern India.JNeurosci Rural Pract 2014;5(4):340-348

2 Hayreh SS.Ischemic optic neuropathies-where are we now?Graefes Arch Clin Exp Ophthalmol2013;251(8):1873-1874

3 Chua D,Cullen JF.Incipient non-arteritic anterior ischaemic optic neuropathy:a distinct clinical entity,the Singapore scene 3.SingaporeMed J2014;55(9):473-475

4 Hayreh SS.Ocular vascular occlusive disorders:natural history of visual outcome.Prog Retin Eye Res2014;41:1-25

5韋企平,魏世輝.視神經(jīng)疾病中西醫(yī)結(jié)合診治.北京:人民衛(wèi)生出版社2007:93-99

6宋琛.缺血性眼病治療新概念.北京:人民軍醫(yī)出版社2005:94-155 7 Chen T,Ma J,Zhong Y.Research advances in the risk factors of nonarteritic anterior ischemic optic neuropathy.Zhonghua Yan Ke Za Zhi 2013;49(11):1049-1051

8 Reddy D,Rani PK,Jalali S,et al.A Study of Prevalence and Risk Factors of Diabetic Retinopathy in Patients with Non-Arteritic Anterior Ischemic Optic Neuropathy(NA-AION).Semin Ophthalmol2015;30 (2):101-104

9常永業(yè),張銘連,石慧君,等.活血通絡(luò)顆粒治療前部缺血性視神經(jīng)病變的臨床觀察.中國中醫(yī)眼科雜志2012;22(2):88-91

10 Chang WT,Choi YH,Vander Heijden R,et al.Traditional processing strongly affects metabolite composition by hydrolysis in Rehmannia glutinosa roots.Chem Pharm Bull2011;59(5):546-552

11李紅偉,孟祥樂.地黃化學(xué)成分及其藥理作用研究進展.藥物評價研究2015;38(2):218-228

12 Gao HJ,Liu PF,Li PW,et al.Ligustrazine monomer against cerebral ischemia/reperfusion injury.Neural Regen Res2015;10(5):832-840

13 Lin KH,Kuo WW,Jiang AZ,et al.Tetramethylpyrazine Ameliorated Hypoxia-Induced Myocardial Cell Apoptosis via HIF-1α/JNK/p38 and IGFBP3/BNIP3 Inhibition to Upregulate PI3K/Akt Survival Signaling.Cell Physiol Biochem2015;36(1):334-344

14 Li P,Li Z.Neuroprotective effect of paeoniflorin on H2O2-induced apoptosis in PC12 cells by modulation of reactive oxygen species and the inflammatory response.Exp Ther Med2015;9(5):1768-1772

15 Yan LG,Ruan JS,Zhang L,et al.Effect of aqueous extracts of several kinds of herbs on human platelet aggregation and expression of P-selectin in vitro.Chin J Integr Med 2015;21(4):286-290

16 Ajdanovi V,Jakovljevi V,Milenkovi D,et al.Positive effects of naringenin on near-surface membrane fluidity in human erythrocytes. Acta Physiol Hung 2015;102(2):131-136

17 Chang CY,Kao TK,Chen WY,et al.Tetramethylpyrazine inhibits neutrophil activation following permanent cerebral ischemia in rats. Biochem Biophys Res Commun 2015;463(3):421-427

18 Hu J,Lang Y,Cao Y,et al.The Neuroprotective Effect of Tetramethylpyrazine Against Contusive Spinal Cord Injury by Activating PGC-1α in Rats.Neurochem Res 2015;40(7):1393-1401

19 Jiang B,Shen RF,Bi J,et al.Catalpol:a potential therapeutic for neurodegenerative diseases.Curr Med Chem 2015;22(10):1278-1291 20 Teng L,Hong F,Zhang C,et al.Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease.Neural Regen Res2014;9(4):407-412

21譚靈莉,崔丹丹,?；埒P,等.梓醇對腦缺血后神經(jīng)血管單元構(gòu)筑的影響.中國藥理學(xué)通2014;30(1):44-48

22王曉麗,王毅,張賽,等.紅花黃色素對大鼠腦缺血再灌注損傷的保護作用.中華實用診斷與治療雜志2014;28(1):12-14

23 Li LJ,Li YM,Qiao BY,et al.The value of safflower yellow injection for the treatment of acute cerebral infarction:a randomized controlled trial.Evid Based Complement Alternat Med2015:478793

24 Liu Y,Tian X,Cui M,et al.Safflower yellow inhibits angiotensin II-induced adventitial fibroblast proliferation and migration.J Pharmacol Sci2014;126(2):107-114

25 Han B,Hu J,Shen J,et al.Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.Eur J Pharmacol2013;714(1-3):83-88

26 Yang G,Zhou X,Chen T,et al.Hydroxysafflor yellow A inhibits lipopolysaccharide-induced proliferation and migration of vascular smooth muscle cells via Toll-like receptor-4 pathway.Int J Clin Exp Med2015; 8(4):5295-5302

27 Zhou MX,Fu JH,Zhang Q,et al.Effect of hydroxy safflower yellow A on myocardial apoptosis after acute myocardial infarction in rats.Genet Mol Res2015;14(2):3133-3141

28 Chen C,Du P,Wang J,et al.Paeoniflorin ameliorates acute myocardial infarction of rats by inhibiting inflammation and inducible nitric oxide synthase signaling pathways.Mol Med Rep2015;12(3): 3937-3943

29 Zhang Y,Li H,Huang M,et al.Paeoniflorin,a Monoterpene Glycoside,Protects the Brain from Cerebral Ischemic Injury via Inhibition of Apoptosis.Am J Chin Med2015;43(3):543-557

30 Li W,Qi Z,Wei Z,et al.Paeoniflorin inhibits proliferation and induces apoptosis of human glioma cells via microRNA-16 upregulation and matrix metalloproteinase-9 downregulation.Mol Med Rep2015;12(2): 2735-2740

31 Wang Z,Liao SG,He Y,et al.Protective effects of fractions from Pseudostellaria heterophylla against cobalt chloride-induced hypoxic injury in H9c2 cell.J Ethnopharmacol2013;147(2):540-545

32 Ghofrani S,Joghataei MT,Mohseni S,et al.Naringenin improves learning and memory in an Alzheimer's disease rat model:Insights into the underlying mechanisms.Eur J Pharmacol2015;764:195-201

33 Jangra A,Kasbe P,Pandey SN,et al.Hesperidin and Silibinin Ameliorate Aluminum-Induced Neurotoxicity:Modulation of Antioxidants and Inflammatory Cytokines Level in Mice Hippocampus.Biol Trace Elem Res2015[Epub ahead of print]

34 Khan MH,Parvez S.Hesperidin ameliorates heavy metal induced toxicity mediated by oxidative stress in brain of Wistar rats.J Trace ElemMed Biol2015;31:53-60

35王玉紅,程霞,陳光輝.地黃化學(xué)成分研究及治療心血管疾病的臨床應(yīng)用.中西醫(yī)結(jié)合心腦血管病雜志2009;7(12):1450-1452

36 Bao LD,Wang Y,Ren XH,et al.Hypolipidemic effect of safflower yellow and primary mechanism analysis.Genet Mol Res2015;14(2):6270-6278

37程敏,胡正海.女貞子的生物學(xué)和化學(xué)成分研究進展.中草藥2010;41(7):1219-1221

38 Hu J,Pang W,Chen J,et al.Hypoglycemic effect of polysaccharides with different molecular weight of Pseudostellaria heterophylla.BMCComplement Altern Med 2013;13:267

39李小玲,李菁,朱偉杰,等.絲瓜絡(luò)對高脂血癥小鼠LDL-R基因表達的影響.中國病理生理雜志2009;25(6):1156-1159

40 Zhang LN,Jin GQ,Zhang XL,et al.Effects of 5-hydroxymethyl furfural extracted from Rehmannia glutinosa Libosch on the expression of signaling molecules relevant to learning and memory among hippocampal neurons exposed to high concentration of corticosterone.Chin J IntegrMed 2014;20(11):844-949

41 Li X,Zhou M,Shen P,et al.Chemical constituents from Rehmannia glutinosa.Zhongguo Zhong Yao Za Zhi2011;36(22):3125-3129

42 Liu Y,Yin H,Jiang Y,et al.Correlation between Platelet Gelsolin and Platelet Activation Level in Acute Myocardial Infarction Rats and Intervention Effect of Effective Components of Chuanxiong Rhizome and Red Peony Root.Evid Based Complement Alternat Med 2013:985746

43 Yan LG,Ruan JS,Zhang L,et al.Effect of aqueous extracts of several kinds of herbs on human platelet aggregation and expression of P-selectinin vitro.Chin J Integr Med2015;21(4):286-290

Clinical studies of Huoxuetongluo granula on the treatment of ischemicoptic neuropathy

Cheng-YiZhu1,Qiong Yi1,Jin-Li M a1,Qi-Ping Wei2

1Department of Ophthalmology,Hepingli Hospital,Beijing 100013,China;2Department of Ophthalmology,Dongfang Affiliated Hospital of Beijing University of Chinese Medicine,Beijing 100078,China

Qi-Ping Wei.Department of Ophthalmology, Dongfang Affiliated Hospital of Beijing University of Chinese Medicine,Beijing 100078,China.wei_dfyy@yahoo.com.cn

·AIM:To evaluate the clinical efficacy of Huoxuetongluo granula on the treatment of qideficiency and blood stasis type of non-arteritic anterior ischemic optic neuropathy (NAION).·METHODS:A total of 100 patients with NAION were enrolled in the randomized controlled trial.They were divided in to control group(49 cases with 70 eyes)and treatment group(51 cases with 72 eyes).The patients in control group were treated with only injections of compound anisodine(CA)beside superficial temporal artery,2m l each time,once per day.The patients in treatment group received huoxuetongluo granula,10g each time,twice per days,besides CA.Patients were followed up for 3m o,and the overall cure effect,visual acuity,mean sensitivity(MS),serum lipid levels and hemorheology indicators were measured and analyzed.·RESULTS:After treatments,the total effective rate of treatment group were 88.2%,which was significantly higher than that of the control group(71.4%)(Z=2.890, P=0.004).Com pared with the control group,the visual acuity and MS of treatment group were significantly higher and the differences were statistical(t=-4.65,P＜0.0001;t=-3.69,P=0.0004).The TC,TG and lowdensity lipoprotein cholesterol(LDL-C)levels were significantly lower,the high-density lipoprotein cholesterol(HDL-C)significantly increased than those before treatments(t=6.25,P＜0.01;t=4.14,P＜0.01;t= 4.48,P＜0.01;t=3.76,P=0.0003;t=-4.31,P＜0.01).After treatments,the whole blood high shear viscosity,low shear viscosity,plasma viscosity and fibrinogen of the treatment group were significantly lower than those of control group(t=3.40,P=0.0011;t=5.75;P＜0.01;t=3.61, P=0.0005;t=6.78,P＜0.01;t=3.13,P=0.0025).·CONCLUSION:The combination of CA and huoxuetongluo granula can improve the visual acuity, MS,serum lipid levels and hemorheology indicators significantly.

optic neuropathy;hemorheology; huoxuetongluo granula

朱成義,碩士,主治醫(yī)師,研究方向:中西醫(yī)結(jié)合治療眼底病、神經(jīng)眼科疾病的診療。

韋企平,主任醫(yī)師,研究方向:眼底病.wei_dfyy@ yahoo.com.cn

2015-08-04

2015-10-22

:Zhu CY,Yi Q,Ma JL,et al.Clinical studies of Huoxuetongluo granula on the treatment of ischemic optic neuropathy. Guoji Yanke Zazhi(Int Eye Sci)2015;15(11):1945-1948

10.3980/j.issn.1672-5123.2015.11.29

Received:2015-08-04 Accepted:2015-10-22

方法:采用隨機對照試驗,將100例非動脈炎性前部缺血性視神經(jīng)病變患者隨機分為對照組和治療組,治療組51例72眼,對照組49例70眼。對照組給予復(fù)方樟柳堿注射液顳淺動脈旁注射,2mL/次,1次/d。在上述治療的基礎(chǔ)上,治療組患者加用活血通絡(luò)顆粒(10g/次,口服,2次/d)進行干預(yù)。3mo后,觀察并分析兩組患者視神經(jīng)病變的總體療效、視力、視野平均光敏感度、血脂水平及血液流變學(xué)指標的改善情況。

結(jié)果:治療后,治療組患者視神經(jīng)病變的總有效率為88.2%,顯著高于對照組71.4%(Z=2.890,P=0.004);治療組患者的視力和視野平均敏感度均顯著性提高,差異有統(tǒng)計學(xué)意義(t=-4.65,P＜0.01;t=-3.69,P= 0.0004);治療組患者的血清總膽固醇、甘油三脂、低密度脂蛋白膽固醇水平較治療前均下降,高密度脂蛋白膽固醇較治療前升高,差異有統(tǒng)計學(xué)意義(t=6.25,P＜0.01;t= 4.14,P＜0.01;t=4.48,P＜0.01;t=3.76,P= 0.0003;t=-4.31,P＜0.01);治療組患者的全血高切黏度、低切黏度、血漿黏度和血漿纖維蛋白原均顯著降低(t= 3.40,P=0.0011;t=5.75,P＜0.01;t=3.61,P=0.0005;t= 6.78,P＜0.01;t=3.13,P=0.0025)。

結(jié)論:復(fù)方樟柳堿注射液聯(lián)合活血通絡(luò)顆?？娠@著改善NAION患者的視力、視野、血脂水平和血液流變學(xué)指標。